Amicus Therapeutics, Inc. provided revenue guidance for the full-year of 2022. For the year the company anticipates total Galafold revenue growth between 15% and 20% at CER driven by continued underlying demand from both switch and treatment-naive patients, geographic expansion, the continued diagnosis of new Fabry patients and commercial execution across all major markets, including the U.S., EU, U.K., and Japan. Applying average October 2022 exchange rates, the negative currency impact on full-year 2022 Galafold reported sales would be approximately 9%.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.02 USD | +2.14% |
|
+1.01% | -29.39% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-29.39% | 2.97B | |
+18.97% | 45.34B | |
+41.98% | 40.42B | |
-10.06% | 37.92B | |
+31.15% | 31.75B | |
-7.79% | 27.71B | |
+13.32% | 26.52B | |
+43.05% | 13.96B | |
+31.28% | 12.44B | |
-7.41% | 11.26B |
- Stock Market
- Equities
- FOLD Stock
- News Amicus Therapeutics, Inc.
- Amicus Therapeutics, Inc. Provides Revenue Guidance for the Full-Year of 2022